Drug-induced rheumatic diseases.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D006073:Gout / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D009220:Myositis / Q000139:chemically induced; D010018:Osteomalacia / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced; D010024:Osteoporosis / Q000139:chemically induced; D011342:Procainamide / Q000009:adverse effects; D012216:Rheumatic Diseases / Q000139:chemically induced*; D012595:Scleroderma, Systemic / Q000139:chemically induced; D013963:Thyroid Hormones / Q000009:adverse effects; D014527:Uric Acid / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D000927:Anticonvulsants; D000970:Antineoplastic Agents; D004232:Diuretics; D013963:Thyroid Hormones; D014527:Uric Acid; D006830:Hydralazine; D006493:Heparin; D011342:Procainamide